BBLG Bone Biologics Corporation
Listings ·
Nasdaq says the closing bid has been below $1 for 30 consecutive business days. The company completed a 1-for-6 reverse split in June 2025 and plans to seek approval for another at its next annual meeting.
A single healthcare-focused institutional investor bought the shares. The company says the financing extends its runway through Q2 2027, and warrants could add up to about $6.0 million more if exercised for cash.
Bone Biologics sold pre-funded warrants for 2,112,677 shares at a combined $1.419 each, with Series F and G warrants at $1.42, through H.C. Wainwright & Co. Net proceeds were about $2.7 million, and the 10-K carries a going-concern warning.
Bone Biologics says its June offering raised $5 million gross and that it expects cash to fund operations into the second quarter of 2026, while enrollment in its pilot study is slower than planned.
Nasdaq says Bone Biologics has met the $1.00 bid price rule after a 10-day run, but the release gives no share price, and its lead product still needs FDA approval before sale.
Bone Biologics Corporation is a medical device company focused on bone regeneration in spinal fusion using NELL-1, a recombinant human protein. NELL-1 is licensed exclusively for worldwide applications through a technology transfer from the UCLA Technology Development Group on behalf of UC Regents. Its lead product candidate, NB1, combines NELL-1 with demineralized bone matrix (DBM) from MTF Biologics and is intended for lumbar spinal fusion. The FDA has guided that NELL-1/DBM will be classified as a device/drug combination product that requires a pre-market approval (PMA) application before commercialization in the United States. A pilot clinical study in Australia will evaluate NB1 in up to 30 adult subjects undergoing transforaminal lumbar interbody fusion (TLIF) for degenerative disc disease. The study design was reviewed by the FDA's Division of Orthopedic Devices in a Pre-submission to support progression to a pivotal trial in the United States. The company says NELL-1 may also apply to non-union trauma cases and osteoporosis. The company describes itself as a clinical-stage entity.
| Product or program | What it is | Stage |
|---|---|---|
| NB1 (NELL-1/DBM Fusion Device) | NELL-1 protein combined with DBM for lumbar spinal fusion | First-in-man pilot clinical study initiated in Australia |
| NELL-1 platform | Recombinant bone growth protein licensed from UCLA TDG | Two preclinical sheep studies completed |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $1.1 million | $2.1 million |
| Net income (loss) | -$3.1 million | -$4.1 million |
| Cash from operations | -$2.7 million | -$4.1 million |
Our latest story on this, dated Sep 16, 2026: "Bone Biologics gets Nasdaq minimum bid price notice, has until March 9, 2027". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 9, 2026: "Bone Biologics closes private placement of pre-funded warrants, about $2.7 million net". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 23, 2026: "Bone Biologics completes $3.0 million private placement with warrants". The story links the filing or release it is based on. Read the story.
Bone Biologics Corporation trades under the ticker BBLG on NASDAQ.
Bone Biologics Corporation is listed on NASDAQ.
The SEC Central Index Key (CIK) for Bone Biologics Corporation is 1419554. Its filings are on SEC EDGAR.
2,756,057 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Bone Biologics Corporation under United States.
Our directory classifies Bone Biologics Corporation as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Bone Biologics Corporation is US0980706008.
aibio.space lists Bone Biologics Corporation among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Bone Biologics Corporation is a medical device company focused on bone regeneration in spinal fusion using NELL-1, a recombinant human protein. NELL-1 is licensed exclusively for worldwide applications through a technology transfer from the UCLA Technology Development Group on behalf of UC Regents.
NB1 (NELL-1/DBM Fusion Device): NELL-1 protein combined with DBM for lumbar spinal fusion Stage: First-in-man pilot clinical study initiated in Australia.
NELL-1 platform: Recombinant bone growth protein licensed from UCLA TDG Stage: Two preclinical sheep studies completed.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form S-1. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio